Search

everythinglearnresearchcommunity

for

Search:↓

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Finasteride does not prevent bladder cancer.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Androgen deprivation therapy might be better for preventing COVID-19 than treating it.

Finasteride may cause breast enlargement, low testosterone a risk factor.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Finasteride reduces PSA levels by around 40-50% in BPH patients.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.

KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.

Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.

Androgen receptors in the mouse brain may explain cognitive and mood changes in prostate cancer treatment.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.

The document highlights recent findings and treatments in urology, including prostate cancer diagnostics, urinary incontinence, and new therapies.

Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.

Finasteride helps reduce heart issues and improves heart function.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by blocking male sex hormones.

Testosterone replacement therapy improves libido, mood, muscle strength, and bone density in men with Testosterone Deficiency Syndrome.

Men, particularly those with hair loss, are more likely to get the virus, and those with prostate cancer may have milder symptoms. Testosterone's role in the disease is unclear, and the virus doesn't seem to harm male fertility. Women with PCOS might be at higher risk. More research is needed.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

Low testosterone in men is a risk factor for a specific heart rhythm issue, and testosterone treatment may help prevent it.